Glass Lewis Backs Pacira’s Board Nominees, Cites 37% Return and 21 Patents
PCRX•Glass Lewis recommends Pacira stockholders vote for the company’s three director nominees and reject DOMA’s slate ahead of the June 9, 2026 annual meeting. It highlighted Pacira’s 37% one-year and 23.8% returns under the 5x30 strategy, Phase 2 assets PCRX-201 and PCRX-2002 and 21 Orange Book patents supporting value creation.
1. Glass Lewis Proxy Recommendation
Glass Lewis recommends that stockholders vote for Pacira’s three director nominees—Christopher Christie, Samit Hirawat, MD and Thomas Wiggans—and vote against DOMA Perpetual Capital Management’s three nominees on the white proxy card ahead of the June 9, 2026 annual meeting. The recommendation underscores confidence in the existing board’s leadership and strategic vision under CEO Frank Lee.
2. Performance Metrics and Strategic Drivers
The proxy advisor noted Pacira’s 37% total stockholder return for calendar 2025 and 23.8% cumulative return since launching its 5x30 strategy, citing these metrics as evidence of momentum. Glass Lewis also pointed to the Phase 2 pipeline candidates PCRX-201 and PCRX-2002 expected to drive topline growth beyond 2030, along with the filing of 21 Orange Book patents to protect and extend intellectual property.
3. Critique of Dissident Slate and Voting Instructions
Glass Lewis concluded that DOMA’s nominees lack the requisite skills to execute a strategic review or value-creation plan and that their proposals introduce undue risk without clear benefits. Pacira has urged all stockholders to submit votes using the BLUE proxy card and to disregard any white cards from DOMA, emphasizing that every vote is critical to maintaining continuity of the 5x30 plan.
